CellaVision AB (publ)
CLVSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.03 | 3.06 | -8.53 | 1.47 |
| FCF Yield | 1.77% | 2.74% | 1.22% | 1.02% |
| EV / EBITDA | 30.55 | 19.10 | 29.18 | 38.17 |
| Quality | ||||
| ROIC | 15.40% | 15.45% | 15.76% | 17.42% |
| Gross Margin | 67.35% | 68.37% | 68.56% | 69.37% |
| Cash Conversion Ratio | 1.12 | 1.51 | 0.92 | 1.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.19% | 6.19% | 10.69% | 6.99% |
| Free Cash Flow Growth | 9.76% | 62.06% | -10.03% | 101.27% |
| Safety | ||||
| Net Debt / EBITDA | -0.56 | -0.27 | -0.03 | 0.03 |
| Interest Coverage | 94.21 | 51.24 | 67.64 | 87.21 |
| Efficiency | ||||
| Inventory Turnover | 1.89 | 1.70 | 1.41 | 1.51 |
| Cash Conversion Cycle | 206.36 | 219.72 | 240.13 | 221.89 |